Compare the progression of disease and overall survival in patients with transthyretin amyloidosis with and without liver transplant
Evaluate treatment modalities that may benefit patients with TTR amyloidosis
Foster an international community of medical experts who will develop recommendations on the clinical management of patients with transthyretin amyloidosis
Financial support for the THAOS Registry has been provided by Pfizer. The THAOS Registry is overseen by a scientific board composed of scientific and clinical experts in the field of amyloid disease, including Pfizer representation. Pfizer is the legal owner of all survey data and may use the data for purposes including regulatory submissions.
The information presented in this site is intended for health care professionals.